STOCK TITAN

YS Biopharma Co., Ltd. - $YS STOCK NEWS

Welcome to our dedicated page for YS Biopharma Co., Ltd. news (Ticker: $YS), a resource for investors and traders seeking the latest updates and insights on YS Biopharma Co., Ltd. stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect YS Biopharma Co., Ltd.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of YS Biopharma Co., Ltd.'s position in the market.

Rhea-AI Summary

YS Biopharma announced a name change to LakeShore Biopharma, effective May 24, 2024. This rebranding aims to align with the company's global market positioning. The ticker symbol on Nasdaq will change from 'YS' to 'LSB' starting May 28, 2024. Shareholders' rights and the company's financial position remain unaffected. The CUSIP number will also stay the same.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.46%
Tags
none
-
Rhea-AI Summary

YS Biopharma has announced the results of its Extraordinary General Meeting (EGM) held on May 21, 2024, in Hong Kong. Key resolutions passed include renaming the company to LakeShore Biopharma and appointing new directors Dave Chenn, Chunyang Shao, Zengjun Xu, Thomas Xue, and Adam Zhao. Additionally, the 2024 Share Incentive Plan was approved, and previous resolutions from the February 22, 2024 meeting were reaffirmed. The company is updating its records with the Cayman Islands Registrar and working with Nasdaq to update its trading symbols.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.22%
Tags
none
-
Rhea-AI Summary

YS Biopharma, a global biopharmaceutical company, will hold an Extraordinary General Meeting on May 21, 2024, to change its name to LakeShore Biopharma and appoint new directors. Mr. Dave Chenn has been appointed as the Interim CEO with vast experience in technology, finance, and healthcare sectors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.75%
Tags
management
Rhea-AI Summary

YS Biopharma has received an additional 180-day extension from Nasdaq to regain compliance with the minimum bid price rule. The company did not meet the $1.00 bid price requirement and now has until October 21, 2024, to demonstrate compliance. Failure to do so may result in delisting.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.75%
Tags
none
-
Rhea-AI Summary
YS Biopharma announces unaudited financial results for the first nine months of fiscal year 2024, highlighting revenue decline due to supply chain disruptions but increased gross margin. Positive clinical trial results for next-generation rabies vaccine and approval for immunotherapeutic vaccine in the Philippines signal growth opportunities. The Company focuses on operational enhancements, cost controls, and future product commercialization to drive shareholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.2%
Tags
-
Rhea-AI Summary
YS Biopharma has been granted approval by the Philippine Food and Drug Administration to conduct a Phase I clinical trial for its YS-HBV-002 immunotherapeutic vaccine for chronic hepatitis B virus infection. The vaccine aims to address the significant unmet medical need for effective therapies for chronic HBV patients, with the trial expected to begin in June 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.65%
Tags
Rhea-AI Summary
YS Biopharma to report first nine months of fiscal year 2024 financial results on April 19, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.07%
Tags
conferences earnings
-
Rhea-AI Summary
YS Biopharma Co., announces positive interim results from the Phase 3 Trial of its PIKA Rabies Vaccine, showing potential for accelerated protection in a 7-day regimen. The vaccine, utilizing proprietary technology, demonstrated superior immunogenicity and safety compared to existing vaccines, with a higher seroconversion rate by Day 7. The Trial involves 4,500 participants and aims to replace conventional 3-4 week regimens with a shorter treatment period.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.41%
Tags
-
Rhea-AI Summary
YS Biopharma Co., (Nasdaq: YS) announced the full repayment of a US$40,000,000 loan, enhancing its financial position and flexibility. The repayment removes royalty obligations, allowing the company to focus on executing its business plan and improving its capital structure.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.42%
Tags
none
Rhea-AI Summary
YS Biopharma Co., Ltd. announces changes to its board of directors and key strategic appointments in China. Two directors resign, new appointments made within subsidiaries. The Board now consists of ten directors, including key members. Senior officers also appointed, outlining key roles.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
32.03%
Tags
none
YS Biopharma Co., Ltd.

Nasdaq:YS

YS Rankings

YS Stock Data

192.09M
17.10M
81.43%
4.98%
0.05%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
Beijing